In 2008, Galapagos and MorphoSys initiated an alliance in which both companies contribute their core technologies and expertise to discover disease-modifying antibodies directed toward novel targets. Galapagos provides the disease-related biology including the target and cellular assays. The targets are discovered using Galapagos’ SilenceSelect adenoviral target discovery platform. MorphoSys contributes its Ylanthia antibody technology to generate fully human antibodies directed against the target. Galapagos and MorphoSys share the research and development costs equally, as well as all future revenues.
Click here for more information about these alliance programs.